<?xml version="1.0" encoding="UTF-8"?>
<p id="Par134">Pediatric patients should be administered medicines that have been appropriately evaluated for their use. In the past, however, new approved drugs have been used for pediatric patients without assessment of the efficacy and safety in those patients. Clinical studies involving adults with recurrent or refractory HL or ALCL in Japan and other countries demonstrated the efficacy and safety of SGN-35 [
 <xref ref-type="bibr" rid="CR10">10</xref>, 
 <xref ref-type="bibr" rid="CR11">11</xref>]. The present study will prove the efficacy and safety of SGN-35 in Japanese children.
</p>
